IVERIC bio Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
163
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5.9B
IVERIC bio General Information
Description
Developer of biopharmaceutical products designed for the treatment of retinal diseases. The company offers therapeutic candidates and gene therapies for age-related macular degeneration and orphan inherited retinal diseases, providing intravitreal services that inhibit complement factors to reduce disease progression and prevent vision loss in patients with unmet medical needs.
Contact Information
Website
www.ivericbio.comCorporate Office
- 8 Sylvan Way
- Parsippany, NJ 07054
- United States
Corporate Office
- 8 Sylvan Way
- Parsippany, NJ 07054
- United States
IVERIC bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Merger/Acquisition | 11-Jul-2023 | $5.9B | Completed | Generating Revenue/Not Profitable | ||
| 16. 2PO | 05-Dec-2022 | Completed | Generating Revenue/Not Profitable | |||
| 15. PIPE | 22-Jun-2020 | Completed | Generating Revenue/Not Profitable | |||
| 14. PIPE | 01-Jan-2020 | Completed | Generating Revenue/Not Profitable | |||
| 13. PIPE | 30-Oct-2018 | Completed | Generating Revenue/Not Profitable | |||
| 12. Secondary Transaction - Open Market | 17-Apr-2017 | Completed | Generating Revenue/Not Profitable | |||
| 11. Secondary Transaction - Open Market | 15-Apr-2016 | Completed | Generating Revenue/Not Profitable | |||
| 10. PIPE | 24-Aug-2015 | Completed | Generating Revenue/Not Profitable | |||
| 9. Secondary Transaction - Open Market | 15-Apr-2015 | $389M | Completed | Generating Revenue/Not Profitable | ||
| 8. PIPE | 16-Sep-2014 | $50M | $389M | Completed | Generating Revenue/Not Profitable |
IVERIC bio Comparisons
Industry
Financing
Details
IVERIC bio Competitors (79)
One of IVERIC bio’s 79 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI |
IVERIC bio Patents
IVERIC bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024137916-A1 | Pharmaceutical compositions for delivery to the eye | Inactive | 23-Dec-2022 | ||
| WO-2024006902-A2 | Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same | Inactive | 30-Jun-2022 | ||
| WO-2024006902-A3 | Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same | Inactive | 30-Jun-2022 | ||
| WO-2024006902-A9 | Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same | Inactive | 30-Jun-2022 | ||
| CA-3197023-A1 | Methods for treating ophthalmological conditions | Pending | 01-Nov-2020 | C12N15/115 |
IVERIC bio Signals
IVERIC bio Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avoro Capital | Venture Capital | Minority | ||
| Blackstone Life Sciences | Other Private Equity | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority |
IVERIC bio Acquisitions (1)
IVERIC bio’s most recent deal was a Merger/Acquisition with Inception 4 for . The deal was made on 31-Oct-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inception 4 | 31-Oct-2018 | Merger/Acquisition | Biotechnology |
IVERIC bio ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
20.65 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
IVERIC bio FAQs
-
When was IVERIC bio founded?
IVERIC bio was founded in 2007.
-
Where is IVERIC bio headquartered?
IVERIC bio is headquartered in Parsippany, NJ.
-
What is the size of IVERIC bio?
IVERIC bio has 163 total employees.
-
What industry is IVERIC bio in?
IVERIC bio’s primary industry is Pharmaceuticals.
-
Is IVERIC bio a private or public company?
IVERIC bio is a Private company.
-
What is the current valuation of IVERIC bio?
The current valuation of IVERIC bio is .
-
What is IVERIC bio’s current revenue?
The current revenue for IVERIC bio is .
-
How much funding has IVERIC bio raised over time?
IVERIC bio has raised $863M.
-
Who are IVERIC bio’s investors?
Avoro Capital, Blackstone Life Sciences, Foresite Capital, Frazier Healthcare Partners, and HBM Healthcare Investments are 5 of 11 investors who have invested in IVERIC bio.
-
Who are IVERIC bio’s competitors?
Avidity Biosciences, Foventa Therapeutics, Genentech, Adverum Biotechnologies, and ONL Therapeutics are some of the 79 competitors of IVERIC bio.
-
When was IVERIC bio acquired?
IVERIC bio was acquired on 11-Jul-2023.
-
Who acquired IVERIC bio?
IVERIC bio was acquired by Astellas Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process